{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05948111",
            "orgStudyIdInfo": {
                "id": "83338153"
            },
            "organization": {
                "fullName": "Power Life Sciences Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Assessment of Schizophrenia Patients' Clinical Study Experiences",
            "officialTitle": "Insights From Participants: Candid Accounts of Schizophrenia Clinical Trials Patients",
            "therapeuticArea": [
                "Mental Health"
            ],
            "study": "assessment-of-schizophrenia-patients-clinical-study-experiences"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-07",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-08",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-07-07",
            "studyFirstSubmitQcDate": "2023-07-07",
            "studyFirstPostDateStruct": {
                "date": "2023-07-17",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-07-07",
            "lastUpdatePostDateStruct": {
                "date": "2023-07-17",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Power Life Sciences Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The study seeks to delve into the firsthand experiences of patients diagnosed with schizophrenia who partake in a separate clinical trial featuring a specific medical intervention. The primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals.\n\nThe data collected from this study will help improve future outcomes for all schizophrenia patients as well as those in under-represented demographic groups."
        },
        "conditionsModule": {
            "conditions": [
                "Schizophrenia"
            ],
            "keywords": [
                "Schizophrenia"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "CASE_CROSSOVER",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 500,
                "type": "ESTIMATED"
            }
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of schizophrenia patients who decide to enroll in a clinical trial",
                    "timeFrame": "3 months"
                },
                {
                    "measure": "Rate of schizophrenia patients who remain in clinical trial to trial completion",
                    "timeFrame": "12 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of schizophrenia\n* Considered reliable, able to understand, and willing to perform all study procedures\n* Signed Written Informed Consent\n\nExclusion Criteria:\n\n* Currently enrolled in, have completed or have discontinued from a clinical trial involving an investigational drug\n* Is pregnant, breastfeeding or expecting to conceive within the projected duration of the study\n* Any serious and/or unstable pre-existing medical disorders",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Patients with schizophrenia who are actively considering enrolling in an observational clinical study for said condition, but have not yet completed enrollment and randomization phases.",
            "samplingMethod": "PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Michael B Gill",
                    "role": "CONTACT",
                    "phone": "(415) 900-4227",
                    "email": "bask@withpower.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Michael B Gill",
                    "affiliation": "Power Life Sciences Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Power Life Sciences",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94107",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Michael B Gill",
                            "role": "CONTACT",
                            "phone": "415-900-4227",
                            "email": "https://www.withpower.com/contact-us@withpower.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "33887648",
                    "type": "BACKGROUND",
                    "citation": "Runge K, Fiebich BL, Kuzior H, Saliba SW, Yousif NM, Meixensberger S, Nickel K, Denzel D, Schiele MA, Maier SJ, Berger B, Dersch R, Domschke K, Tebartz van Elst L, Endres D. An observational study investigating cytokine levels in the cerebrospinal fluid of patients with schizophrenia spectrum disorders. Schizophr Res. 2021 May;231:205-213. doi: 10.1016/j.schres.2021.03.022. Epub 2021 Apr 19."
                },
                {
                    "pmid": "35219052",
                    "type": "BACKGROUND",
                    "citation": "Srisurapanont M, Kunchanaphongphan T, Chokemaitree N, Prachason T, Kanchanatawan B, Suttajit S, Sanguanvichaikul T, Trisukon W, Dendumrongkul P, Chinvararak C, Kawilapat S. Course and predictors of disability in Thai patients with schizophrenia: A 2-year, multi-center, prospective, observational study. Asian J Psychiatr. 2022 Apr;70:103044. doi: 10.1016/j.ajp.2022.103044. Epub 2022 Feb 19."
                },
                {
                    "pmid": "34986711",
                    "type": "BACKGROUND",
                    "citation": "Garcia-Portilla MP, Benito Ruiz A, Gomez Robina F, Garcia Dorado M, Lopez Rengel PM. Impact on functionality of the paliperidone palmitate three-month formulation in patients with a recent diagnosis of schizophrenia: a real-world observational prospective study. Expert Opin Pharmacother. 2022 Apr;23(5):629-638. doi: 10.1080/14656566.2021.2023496. Epub 2022 Jan 5."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "UNDECIDED"
        }
    },
    "documentSection": {
        "largeDocumentModule": {
            "largeDocs": [
                {
                    "typeAbbrev": "ICF",
                    "hasProtocol": false,
                    "hasSap": false,
                    "hasIcf": true,
                    "label": "Informed Consent Form",
                    "date": "2023-07-07",
                    "uploadDate": "2023-07-07T08:48",
                    "filename": "ICF_000.pdf",
                    "size": 76924
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000012559",
                    "term": "Schizophrenia"
                }
            ],
            "ancestors": [
                {
                    "id": "D000019967",
                    "term": "Schizophrenia Spectrum and Other Psychotic Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M15376",
                    "name": "Schizophrenia",
                    "asFound": "Schizophrenia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M21838",
                    "name": "Schizophrenia Spectrum and Other Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}